Skip to content

Goodwill at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$25.96B-1.8%
Stryker logo
StrykerSYK
$19.19B+0.5%
Globus Medical logo
Globus MedicalGMED
$1.44B+0.4%
AbbVie logo
AbbVieABBV
$35.57B+0.8%
Medtronic logo
MedtronicMDT
$42.59B+2.0%
STERIS logo
STERISSTE
$4.19B+2.4%

Segments

By segment

See full
Specialty Surgery$343.1M
Tissue Reconstruction$270.15M

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's goodwill?
Integra LifeSciences (IART) reported goodwill of $613.25M in Q1 2026.
How has Integra LifeSciences's goodwill changed year-over-year?
Integra LifeSciences's goodwill decreased by 44.5% year-over-year, from $1.11B to $613.25M.
What is the long-term trend for Integra LifeSciences's goodwill?
Over 5 years (2020 to 2025), Integra LifeSciences's goodwill has grown at a -8.0% compound annual growth rate (CAGR), from $932.37M to $615.16M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.